SMYD3 and prostate carcinoma: Additionally, the authors identified that SMYD3-depleted prostate cancer cells show S phase arrest, and this correlates with increased expression of cyclin D2 (CCND2), a key cell cycle regulator at the G1/S checkpoint that has been shown to be frequently silenced in prostate carcinomas [61, 62].